Outcome of Allotment Committee Meeting
Sun Pharmaceutical Industries Ltd has informed BSE that the Allotment Committee of Directors at its meeting held on February 12, 2016, allotted:1. 32,449 (Thirty Two Thousand Four Hundred and Forty Nine) equity shares of the Company of Re. 1/- each, on exercise of stock options under the Sun Employee Stock Option Scheme - 2015.2. 30,000 (Thirty Thousand) equity shares of the Company of Re. 1/- each, to Sun Pharma ESOP Trust under... Sun Pharma: Merger queered the pitch
The stock of the countrys largest drug maker, Sun Pharmaceutical, has lost over 10 per cent in the past year. This was on two counts. First, weak performance beginning March 2015 quarter following co... Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
Sudhir V Valia has submitted the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 to BSE Sun Pharma, Lupin launch generics in US
Product launches will give boost to US businesses of two companies Sun Pharma Bets on Cut-Price Gleevec To Boost US Sales
Sun Pharma launched a generic version of Novartis's leukaemia drug Gleevec on Monday in the United States and hopes to poach a third of sales in six months by pricing the copycat some 30 per cent chea... Update on Sale of CNS divisions of erstwhile Ranbaxy to Strides Shasun Limited (formerly known as Strides Arcolab Ltd) - Closure of transaction
With reference to the earlier press release dated September 19, 2015 regarding 'Strides Arcolab acquires CNS divisions of erstwhile Ranbaxy', and further update vide letter dated January 22, 2016 informing regarding receipt of approval from the Competition Commission of India (CCI) for the said transaction.Further to the above, Sun Pharmaceutical Industries Ltd has now informed BSE that all the necessary formalities for Closure of the said... Sun Pharma launches Imatinib Mesylate in USA
Sun Pharmaceutical Industries Ltd has informed BSE regarding a Press Release dated February 01, 2016 titled "Sun Pharma launches Imatinib Mesylate in USA". M-cap of top 10 cos jumps by 1.02 lakh cr
The combined market valuation of top 10 most valued Indian companies advanced by a whopping Rs 1,02,667 crore last week, with Sun Pharma and TCS winning big amid a recovery in the broader market.The ... Shareholding for the Period Ended December 31, 2015
Sun Pharmaceutical Industries Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2015. For more details, kindly Click here Sun Pharma to announce third quarter results on February 12, 2016
Sun Pharmaceutical Industries Ltd has informed BSE regarding a Press Release dated January 30, 2016 titled "Sun Pharma to announce third quarter results on February 12, 2016".